ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 308.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 75.25M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $308.08M | $75.25M | (m) |
| 2026-03-31 | (m) | $295.41M | $73.09M | (m) |
| 2025-12-31 | (m) | $276.98M | $71.36M | (m) |
| 2025-09-30 | (m) | $252.75M | $71.18M | (m) |
| 2025-06-30 | (m) | $205.22M | $69.69M | (m) |
| 2025-03-31 | (m) | $189.53M | $71.01M | (m) |
| 2024-12-31 | (m) | $178.96M | $72.08M | (m) |
| 2024-09-30 | (m) | $177.28M | $73.65M | (m) |
| 2024-06-30 | (m) | $168.77M | $76.33M | (m) |
| 2024-03-31 | (m) | $174.50M | $74.92M | (m) |
| 2023-12-31 | (m) | $170.28M | $75.55M | (m) |
| 2023-09-30 | (m) | $179.69M | $72.53M | (m) |
| 2023-06-30 | (m) | $189.60M | $68.09M | (m) |
| 2023-03-31 | (m) | $184.34M | $63.40M | (m) |
| 2022-12-31 | (m) | $185.31M | $57.91M | (m) |
| 2022-09-30 | (m) | $168.04M | $55.68M | (m) |
| 2022-06-30 | (m) | $159.68M | $54.96M | (m) |
| 2022-03-31 | (m) | $154.52M | $52.50M | (m) |
| 2021-12-31 | (m) | $154.34M | $49.30M | (m) |
| 2021-09-30 | (m) | $146.60M | $41.17M | (m) |
| 2021-06-30 | (m) | $133.43M | $33.03M | (m) |
| 2021-03-31 | (m) | $115.91M | $27.18M | (m) |
| 2020-12-31 | (m) | $98.38M | $22.53M | (m) |
| 2020-09-30 | (m) | $92.41M | $22.26M | (m) |
| 2020-06-30 | (m) | $92.17M | $21.81M | (m) |
| 2020-03-31 | (m) | $93.31M | $22.63M | (m) |
| 2019-12-31 | (m) | $85.07M | $22.27M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $55.66M | $19.67M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $38.45M | $15.68M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |